Core Viewpoint - The company is actively promoting its Alzheimer's treatment drugs, aiming to capture a larger market share in the healthcare sector [2] Company Summary - The company, Jingxin Pharmaceutical (002020.SZ), has two drugs for Alzheimer's treatment: Methylphenidate Hydrochloride Sustained-Release Capsules and Carbamazepine Tartrate Capsules [2] - The company is committed to increasing sales and market presence for these drugs [2] Industry Summary - There is a competitive landscape in the Alzheimer's treatment market, with the company focusing on expanding its reach in both hospital channels and grassroots markets [2]